AI models may aid intrahepatic cholestasis of pregnancy prediction
New artificial intelligence (AI) models based on 11 possible risk factors of intrahepatic cholestasis of pregnancy (ICP) can accurately distinguish between healthy pregnant women,…
Margarida Maia, PhD, Science Writer — 
Articles by Margarida Maia
Livmarli, Bylvay safely reduce pruritus in PFIC, Alagille children
Livmarli (maralixibat) and Bylvay (odevixibat) can help relieve itching, or pruritus, and reduce liver damage in children with progressive familial intrahepatic cholestasis (PFIC) or…
Three-factor tool may predict response to UDCA in PBC: Study
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…
Genetic variant that raises ICP risk is protective against hepatitis B
A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than 16 times, but it likely…
Livdelzi approved in UK as PBC treatment for certain adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…
Top 10 liver disease stories of 2024
In 2024, Liver Disease News kept readers informed aboout liver disease research, treatments, and clinical trials. Here are the 10 most read stories, each with…
Modified scoring system could aid biliary atresia diagnosis: Study
A modified version of the Simple Biliary Atresia Scoring System (SBASS) offers a noninvasive way for doctors to make a biliary atresia diagnosis, differentiating…
Software helps ID hard-to-interpret Alagille-causing gene mutations
Software tools may help predict whether certain hard-to-interpret mutations in the JAG1 gene affect splicing, a process that can direct how a protein is produced,…
Full approval on Ocaliva for primary biliary cholangitis delayed
The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…
Kayfanda wins EU OK for Alagille-related cholestatic pruritus
Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome,…